{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:47:06Z","timestamp":1762145226057,"version":"3.37.3"},"reference-count":79,"publisher":"European Respiratory Society (ERS)","issue":"142","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2016,9,27]]},"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.<\/jats:p>","DOI":"10.1183\/16000617.0084-2016","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T01:26:52Z","timestamp":1480555612000},"page":"381-389","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Future perspectives in pulmonary arterial hypertension"],"prefix":"10.1183","volume":"25","author":[{"given":"G\u00e9rald","family":"Simonneau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vallerie","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"2024102403232511000_25.142.381.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.006974"},{"key":"2024102403232511000_25.142.381.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2024102403232511000_25.142.381.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2024102403232511000_25.142.381.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2024102403232511000_25.142.381.5","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007311"},{"key":"2024102403232511000_25.142.381.6","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0085-2016"},{"key":"2024102403232511000_25.142.381.7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.293"},{"key":"2024102403232511000_25.142.381.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3375"},{"key":"2024102403232511000_25.142.381.9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2016.04.012","article-title":"Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future","volume":"164","author":"Lythgoe","year":"2016","journal-title":"Pharmacol Ther"},{"key":"2024102403232511000_25.142.381.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0927OC"},{"key":"2024102403232511000_25.142.381.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00038903"},{"key":"2024102403232511000_25.142.381.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00045705"},{"key":"2024102403232511000_25.142.381.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.301141"},{"key":"2024102403232511000_25.142.381.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00151313"},{"key":"2024102403232511000_25.142.381.15","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-11-0473"},{"key":"2024102403232511000_25.142.381.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev097"},{"key":"2024102403232511000_25.142.381.17","unstructured":"NCT02664558. A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.18","unstructured":"NCT02736149. Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY2). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.19","unstructured":"NCT01086540. Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.20","unstructured":"NCT02676947. A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension (TRANSFORM-UK). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.21","doi-asserted-by":"crossref","unstructured":"Oudiz R , Meyer C , Chin M , et al. Initial data report from \u201cLARIAT\u201d: a phase 2 study of bardoxolone methyl in PAH patients on stable background therapy. Chest 2015; 148.","DOI":"10.1378\/chest.2345856"},{"key":"2024102403232511000_25.142.381.22","unstructured":"NCT02657356. Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension \u2013 CATALYST. 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.23","unstructured":"NCT02234141. GS-4997 in Adults With Pulmonary Arterial Hypertension (ARROW). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.24","unstructured":"NCT01647945. FK506 (Tacrolimus) in Pulmonary Arterial Hypertension (TransformPAH). 2016. https:\/\/clinicaltrials.gov 2016. Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.25","unstructured":"NCT01447628. IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients. 2016. https:\/\/clinicaltrials.gov 2016. Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.26","unstructured":"NCT01847352. Iron Status and Hypoxic Pulmonary Vascular Responses. 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.27","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1172\/JCI85715","article-title":"Clinical iron deficiency disturbs normal human responses to hypoxia","volume":"126","author":"Frise","year":"2016","journal-title":"J Clin Invest"},{"key":"2024102403232511000_25.142.381.28","unstructured":"NCT01446848. Oral Iron Supplementation in Pulmonary Hypertension. 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837"},{"key":"2024102403232511000_25.142.381.30","unstructured":"NCT02525926. Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension (DENERV'AP). 2016. https:\/\/clinicaltrials.gov Date last accessed: October 21, 2016."},{"key":"2024102403232511000_25.142.381.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8492-5"},{"key":"2024102403232511000_25.142.381.32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004555"},{"key":"2024102403232511000_25.142.381.33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2396"},{"key":"2024102403232511000_25.142.381.34","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008411"},{"key":"2024102403232511000_25.142.381.35","doi-asserted-by":"publisher","DOI":"10.1086\/303059"},{"key":"2024102403232511000_25.142.381.36","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.37.10.741"},{"key":"2024102403232511000_25.142.381.37","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000012754.72951.3D"},{"key":"2024102403232511000_25.142.381.38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s13238-015-0208-7","article-title":"BMPR2 spruces up the endothelium in pulmonary hypertension","volume":"6","author":"Xiong","year":"2015","journal-title":"Protein Cell"},{"key":"2024102403232511000_25.142.381.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65592"},{"key":"2024102403232511000_25.142.381.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2013.08.007"},{"key":"2024102403232511000_25.142.381.41","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037711"},{"key":"2024102403232511000_25.142.381.42","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00100510"},{"key":"2024102403232511000_25.142.381.43","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.147272"},{"key":"2024102403232511000_25.142.381.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.04.038"},{"key":"2024102403232511000_25.142.381.45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq158"},{"key":"2024102403232511000_25.142.381.46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajcn\/79.3.437","article-title":"Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women","volume":"79","author":"Brownlie","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"2024102403232511000_25.142.381.47","doi-asserted-by":"publisher","DOI":"10.1086\/682217"},{"key":"2024102403232511000_25.142.381.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.04.233"},{"key":"2024102403232511000_25.142.381.49","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2014-0021TR"},{"key":"2024102403232511000_25.142.381.50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002569"},{"key":"2024102403232511000_25.142.381.51","doi-asserted-by":"publisher","DOI":"10.1378\/chest.77.4.525"},{"key":"2024102403232511000_25.142.381.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.075"},{"key":"2024102403232511000_25.142.381.53","doi-asserted-by":"publisher","DOI":"10.1086\/685550"},{"key":"2024102403232511000_25.142.381.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.032"},{"key":"2024102403232511000_25.142.381.55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003422"},{"key":"2024102403232511000_25.142.381.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024102403232511000_25.142.381.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2024102403232511000_25.142.381.58","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"2024102403232511000_25.142.381.59","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2024102403232511000_25.142.381.60","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2212"},{"key":"2024102403232511000_25.142.381.61","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2875"},{"key":"2024102403232511000_25.142.381.62","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02044-2014"},{"key":"2024102403232511000_25.142.381.63","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3545"},{"key":"2024102403232511000_25.142.381.64","first-page":"198","article-title":"Animal models of pulmonary hypertension: matching disease mechanisms to etiology of the human disease","volume":"4","author":"Colvin","year":"2014","journal-title":"J Pulm Respir Med"},{"key":"2024102403232511000_25.142.381.65","first-page":"1636","article-title":"The human subject: an integrative animal model for 21st century heart failure research","volume":"7","author":"Chandrasekera","year":"2015","journal-title":"Am J Transl Res"},{"key":"2024102403232511000_25.142.381.66","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/683695","article-title":"Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension","volume":"5","author":"Ross","year":"2015","journal-title":"Pulm Circ"},{"key":"2024102403232511000_25.142.381.67","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0036-2016"},{"key":"2024102403232511000_25.142.381.68","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4539"},{"key":"2024102403232511000_25.142.381.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.026"},{"key":"2024102403232511000_25.142.381.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90160-0"},{"key":"2024102403232511000_25.142.381.71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40256-015-0125-4","article-title":"Novel targets of drug treatment for pulmonary hypertension","volume":"15","author":"Hu","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024102403232511000_25.142.381.72","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0426"},{"key":"2024102403232511000_25.142.381.73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1378\/chest.12-2081","article-title":"Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension","volume":"144","author":"Sadoughi","year":"2013","journal-title":"Chest"},{"key":"2024102403232511000_25.142.381.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200940"},{"key":"2024102403232511000_25.142.381.75","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2024102403232511000_25.142.381.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.05.025"},{"key":"2024102403232511000_25.142.381.77","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2024102403232511000_25.142.381.78","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00057906"},{"key":"2024102403232511000_25.142.381.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.007"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0084-2016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:59:02Z","timestamp":1740373142000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0084-2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":79,"journal-issue":{"issue":"142","published-online":{"date-parts":[[2016,11,30]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1183\/16000617.0084-2016"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0084-2016","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"type":"print","value":"0905-9180"},{"type":"electronic","value":"1600-0617"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}